COL3A1 and SNAP91: novel glioblastoma markers with diagnostic and prognostic value
Metrics: PDF 3603 views | HTML 3053 views | ?
Yuan-Feng Gao1,2, Xiao-Yuan Mao1,2, Tao Zhu1,2, Chen-Xue Mao1,2, Zhi-Xiong Liu3, Zhi-Bin Wang1,2, Ling Li1,2, Xi Li1,2, Ji-Ye Yin1,2, Wei Zhang1,2, Hong-Hao Zhou1,2, Zhao-Qian Liu1,2
1Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, P. R. China
2Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, P. R. China
3Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha 410008, P. R. China
Zhao-Qian Liu, email: [email protected]
Xiao-Yuan Mao, email: [email protected]
Keywords: glioblastoma, novel glioblastoma markers, prognostic value, COL3A1, SNAP91
Received: June 16, 2016 Accepted: August 26, 2016 Published: September 15, 2016
Although patients with glioblastoma (GBM) have grave prognosis, significant variability in patient outcome is observed. This study aims to identify novel targets for GBM diagnosis and therapy. Microarray data (GSE4290, GSE7696, and GSE4412) obtained from the Gene Expression Omnibus was used to identify the differentially expressed genes (DEGs) by significant analysis of microarray (SAM). Intersection of the identified DEGs for each profile revealed 46 DEGs in GBM. A subset of common DEGs were validated by real-time reverse transcription quantitative PCR (qPCR). The prognostic value of some of the markers was also studied. We determined that RRM2 and COL3A1 were increased and directly correlated with glioma grade, while SH3GL2 and SNAP91 were decreased in GBM and inversely correlated with glioma grade. Kaplan-Meir analysis of GSE7696 revealed that COL3A1 and SNAP91 correlated with survival, suggesting that COL3A1 and SNAP91 may be suitable biomarkers for diagnostic or therapeutic strategies for GBM.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.